HIV

Risk factor modification remains key to managing patients with HIV and diabetes.

In this video, Priscilla Hsue, MD, from the University of California San Francisco School of Medicine, explains other health issues patietns with HIV may face as they age.

Motivational interviewing—a patient-centered method to enhance intrinsic motivation by exploring, and resolving ambivalence—has gained a good reputation for increasing adherence.

A 2-part trial shows a new antibody that suppresses HIV when combined with antiretroviral therapy (ART).

Despite universal access to care afforded to US military service members, there is a need to improve and expand access to PrEP for those patients at highest risk for HIV infection.

On National HIV Testing Day, which takes place on June 27, Walgreens and Greater Than AIDS will team up with over 200 health and community organizations to provide free HIV testing and information at Walgreens stores in over 180 cities.

As a result of the persistent opioid epidemic, a current harm reduction initiative focuses on reducing adverse consequences in drug users.

Individuals who inject drugs are at an increased risk of developing invasive methicillin-resistant Staphylococcus aureus (MRSA).

Among HIV-positive women with diabetes, HIV control has improved over time, but diabetes control has not.

When individuals who are at risk for HIV use PrEP, and use it appropriately, risk of infection is significantly lowered.

Top news of the day from across the health care landscape.

A look at last week's top stories in the world of pharmacy.

New research investigates whether reducing the pill burden in HIV treatment regimens could improve patient adherence, retention in care, and virologic outcomes.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses HIV and oncology distinction programs and how these standards bring patients, physicians, and pharmacists together to align care.

A look at last week's top stories in the world of pharmacy.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Brain damage can begin early in infection, particularly during untreated infection, and can cause cognitive impairment.

Top news of the day from across the health care landscape.

The FDA has approved once-daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (Truvada) in combination with safe sex practices, to reduce the risk of sexually acquired HIV-1 in at-risk adolescents..

This article highlights several key therapeutics areas with the prescription medication.

An HIV primary care program is working to reduce the number of new HIV diagnoses and increase viral suppression rates in Long Island and Queens.

The Conference on Retroviruses and Opportunistic Infections (CROI) annually assembles researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS, and related infectious diseases.

The development and uptake of antiretroviral therapy for HIV has reduced the risk of certain cancers were previously prevalent.

Only a small portion of latently infected cells are reactivated by latency-reversing agents.